Effective Treatment of Haemophilus influenzae-Induced Bacterial Conjunctivitis by a Bioadhesive Nanoparticle Reticulate Structure
Source abstract
Abstract
Ocular formulations should provide an effective antibiotic concentration at the site of infection to treat bacterial eye infections. However, tears and frequent blinking accelerate the drug clearance rate and limit drug residence time on the ocular surface. This study describes a biological adhesion reticulate structure (BNP/CA-PEG) consisting of antibiotic-loaded bioadhesion nanoparticles (BNP/CA), with an average 500–600 nm diameter, and eight-arm NH 2 -PEG-NH 2 for local and extended ocular drug delivery. This retention-prolonging effect is a function of the Schiff base reaction between groups on the surface of BNP and amidogen on PEG. BNP/CA-PEG showed significantly higher adhesion properties and better treatment efficacy in an ocular rat model with conjunctivitis in comparison to non-adhesive nanoparticles, BNP, or free antibiotics. Both in vivo safety experiment and in vitro cytotoxicity test verified the biocompatibility and biosafety of the biological adhesion reticulate structure, indicating a promising translational prospect for further clinical use.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Ocular Surface and Contact Lens · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China
Clinical Research Institute, The First People’s Hospital of Foshan, Foshan 528000, China
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou 510275, China
Funding
Science, Technology and Innovation Commission of Shenzhen Municipality · National Natural Science Foundation of China
References (58)
Show source-provided references
1. 10.18502/jovr.v15i3.745610.18502/jovr.v15i3.7456 ↗
2. 10.1016/j.clinthera.2010.03.01310.1016/j.clinthera.2010.03.013 ↗
3. 10.1136/bjophthalmol-2013-30388810.1136/bjophthalmol-2013-303888 ↗
4. 10.2174/1872213x1266618012916571810.2174/1872213x12666180129165718 ↗
5. 10.3949/ccjm.75.7.50710.3949/ccjm.75.7.507 ↗
6. Cronau H. · Am. Fam. Physician · 2010 · 81 · 137
7. 10.1016/j.disamonth.2014.03.00210.1016/j.disamonth.2014.03.002 ↗
8. 10.1542/pir.31-5-19610.1542/pir.31-5-196 ↗
9. 10.2165/11205840-000000000-0000010.2165/11205840-000000000-00000 ↗
10. 10.5497/wjp.v2.i2.4710.5497/wjp.v2.i2.47 ↗
11. 10.1208/s12248-010-9183-310.1208/s12248-010-9183-3 ↗
12. 10.1016/j.addr.2006.07.02210.1016/j.addr.2006.07.022 ↗
13. 10.1021/acs.biomac.5b0152610.1021/acs.biomac.5b01526 ↗
14. 10.1016/j.biomaterials.2020.11996110.1016/j.biomaterials.2020.119961 ↗
15. 10.1021/acsnano.7b0102310.1021/acsnano.7b01023 ↗
16. 10.1021/acsami.9b1385110.1021/acsami.9b13851 ↗
17. 10.3390/nano1007140010.3390/nano10071400 ↗
18. 10.1038/nature0391210.1038/nature03912 ↗
19. 10.1021/nn506599f10.1021/nn506599f ↗
20. 10.1038/nature2230810.1038/nature22308 ↗
21. 10.1038/s41586-019-1791-110.1038/s41586-019-1791-1 ↗
22. 10.1007/bf0319097810.1007/bf03190978 ↗
23. 10.1016/j.ijpharm.2019.01.02910.1016/j.ijpharm.2019.01.029 ↗
24. 10.3389/fbioe.2022.88479710.3389/fbioe.2022.884797 ↗
25. 10.1016/j.ijpharm.2021.12136110.1016/j.ijpharm.2021.121361 ↗
26. 10.3390/pharmaceutics1404077210.3390/pharmaceutics14040772 ↗
27. 10.1007/s13346-015-0262-y10.1007/s13346-015-0262-y ↗
28. 10.1016/j.bioadv.2022.21276710.1016/j.bioadv.2022.212767 ↗
29. 10.1002/smll.20190388010.1002/smll.201903880 ↗
30. 10.1016/j.biomaterials.2020.12060010.1016/j.biomaterials.2020.120600 ↗
31. 10.1126/scitranslmed.aan387910.1126/scitranslmed.aan3879 ↗
32. 10.1021/acsami.0c0667410.1021/acsami.0c06674 ↗
33. 10.1002/smll.20200467710.1002/smll.202004677 ↗
34. 10.1016/j.progpolymsci.2014.07.01010.1016/j.progpolymsci.2014.07.010 ↗
35. 10.3390/polym1003026710.3390/polym10030267 ↗
36. 10.1016/j.ejps.2019.02.01510.1016/j.ejps.2019.02.015 ↗
37. 10.1016/j.addr.2005.07.00510.1016/j.addr.2005.07.005 ↗
38. 10.2147/tcrm.s5824210.2147/tcrm.s58242 ↗
39. 10.1016/j.jconrel.2014.06.04310.1016/j.jconrel.2014.06.043 ↗
40. 10.1016/j.biomaterials.2014.04.03810.1016/j.biomaterials.2014.04.038 ↗
41. 10.1038/nmat442210.1038/nmat4422 ↗
42. 10.1016/j.biomaterials.2019.01.01110.1016/j.biomaterials.2019.01.011 ↗
43. 10.1016/s0142-9612(02)00002-910.1016/s0142-9612(02)00002-9 ↗
44. 10.1111/j.1475-1313.2005.00342.x10.1111/j.1475-1313.2005.00342.x ↗
45. 10.2165/00003495-200969090-0000910.2165/00003495-200969090-00009 ↗
46. 10.1016/j.addr.2017.04.00110.1016/j.addr.2017.04.001 ↗
47. 10.18240/ijo.2019.06.2410.18240/ijo.2019.06.24 ↗
48. 10.1038/s41598-020-79680-610.1038/s41598-020-79680-6 ↗
49. 10.1080/1040844059100218310.1080/10408440591002183 ↗
50. 10.1016/j.cbi.2012.10.02610.1016/j.cbi.2012.10.026 ↗
51. 10.1038/s41551-020-00606-810.1038/s41551-020-00606-8 ↗
52. 10.1016/j.ijbiomac.2015.12.07710.1016/j.ijbiomac.2015.12.077 ↗
53. 10.1197/j.aem.2006.08.00610.1197/j.aem.2006.08.006 ↗
54. 10.3390/pharmaceutics1206057010.3390/pharmaceutics12060570 ↗
55. 10.1128/aac.41.9.196510.1128/aac.41.9.1965 ↗
56. 10.1046/j.1475-1313.2003.00155.x10.1046/j.1475-1313.2003.00155.x ↗
57. 10.1016/j.jconrel.2014.05.03110.1016/j.jconrel.2014.05.031 ↗
58. 10.1016/j.jconrel.2012.01.01910.1016/j.jconrel.2012.01.019 ↗